HIV VACCINE TRIALS NETWORK
Safety and Immunogenicity of mRNAs Encoding HIV Immunogens (eOD-GT8 60mer, Core-g28v2 60mer, N332-GT5 gp151) in Adult Participants Without HIV and in Overall Good Health in South Africa (HVTN 317)
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- HIV Vaccine Trials Network
- Target Recruit Count
- 96
- Registration Number
- NCT06694753
- Locations
- 🇿🇦
Setshaba Research Centre CRS, Soshanguve, Gauteng, South Africa
🇿🇦Soweto HVTN CRS, Soweto, Gauteng, South Africa
🇿🇦Chatsworth CRS, Chatsworth, Kwa Zulu Natal, South Africa
Safety & Immunogenicity of 426c.Mod.Core-C4b Vaccine With 3M-052-AF+Alum in Infants Perinatally Exposed to HIV But Uninfected
- Conditions
- HIV Infections
- Interventions
- Biological: Placebo and DiluentBiological: 3M-052-AF
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- HIV Vaccine Trials Network
- Target Recruit Count
- 22
- Registration Number
- NCT06613789
- Locations
- 🇿🇦
Soweto HVTN CRS, Soweto, Gauteng, South Africa
Evaluating the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibodies in Healthy Participants
- Conditions
- HIV Infections
- Interventions
- Biological: VRC01.23LSBiological: PGT121.414.LSBiological: PGDM1400LS
- First Posted Date
- 2023-07-25
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- HIV Vaccine Trials Network
- Target Recruit Count
- 77
- Registration Number
- NCT05959707
- Locations
- 🇿🇦
Groote Schuur HIV CRS, Cape Town, Western Cape, South Africa
🇿🇦Emavundleni CRS, Klipfontein, Western Cape, South Africa
🇿🇦CAPRISA eThekwini CRS, Durban, South Africa
Evaluating the Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living With and Without HIV in South Africa
- Conditions
- TuberculosisHIV I Infection
- Interventions
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- HIV Vaccine Trials Network
- Target Recruit Count
- 276
- Registration Number
- NCT05947890
- Locations
- 🇿🇦
Johannesburg - CHRU, Westdene, Gauteng,, South Africa
🇿🇦Soweto - Gauteng, Johannesburg, Gauteng, South Africa
🇿🇦Durban - Botha's Hill CRS, Durban, Kwa Zulu Natal, South Africa
Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of HIV-1 Chimp Adenovirus Vaccines Expressing Clade C gp140 & CH505TF gp120 Protein Boost in HIV-uninfected Adult.
- Conditions
- HIV Infections
- Interventions
- Biological: PlaceboBiological: CH505TF gp120
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- HIV Vaccine Trials Network
- Target Recruit Count
- 34
- Registration Number
- NCT05182125
- Locations
- 🇿🇦
Emavundleni CRS, Cape Town, South Africa
🇿🇦CAPRISA eThekwini CRS, Durban, South Africa
🇿🇦Isipingo CRS, Isipingo, South Africa
Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study
- Conditions
- HIV Infection
- Interventions
- Other: Analytical Treatment Interruption
- First Posted Date
- 2021-04-26
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- HIV Vaccine Trials Network
- Target Recruit Count
- 13
- Registration Number
- NCT04860323
- Locations
- 🇧🇼
Gaborone CRS, Gaborone, Botswana
🇲🇼Blantyre CRS, Blantyre, Malawi
🇲🇼Malawi CRS, Lilongwe, Malawi
Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 704/HPTN 085 AMP Study
- Conditions
- HIV Infection
- Interventions
- Other: Analytical Treatment Interruption
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- HIV Vaccine Trials Network
- Target Recruit Count
- 18
- Registration Number
- NCT04801758
- Locations
- 🇧🇷
Instituto de Pesquisa Clinica Evandro Chagas (IPEC), FIOCRUZ, Rio de Janeiro, Brazil
🇵🇪Asociacion Civil Selva Amazonica (ACSA), Iquitos CRS, Iquitos, Maynas, Peru
🇵🇪Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales, San Marcos CRS, Callao, Peru
Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants
- Conditions
- HIV Infections
- Interventions
- Biological: CH505TF gp120Biological: PlaceboBiological: GLA-SE adjuvant
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- HIV Vaccine Trials Network
- Target Recruit Count
- 38
- Registration Number
- NCT04607408
- Locations
- 🇿🇦
Perinatal HIV Research Unit (PHRU), Soweto CRS, Johannesburg, Gauteng, South Africa
Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19
- Conditions
- SARS-CoV-2COVID-19
- Interventions
- Other: Sample collection
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- HIV Vaccine Trials Network
- Target Recruit Count
- 759
- Registration Number
- NCT04403880
- Locations
- 🇺🇸
Alabama Vaccine CRS, Birmingham, Alabama, United States
🇺🇸UCLA CARE Center CRS, Los Angeles, California, United States
🇺🇸Bridge HIV CRS, San Francisco, California, United States
An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
- Conditions
- HIV Infections
- Interventions
- Other: Observation
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2022-04-18
- Lead Sponsor
- HIV Vaccine Trials Network
- Target Recruit Count
- 209
- Registration Number
- NCT03337906
- Locations
- 🇺🇸
Alabama Vaccine CRS, Birmingham, Alabama, United States
🇺🇸Bridge HIV CRS, San Francisco, California, United States
🇺🇸The Hope Clinic of the Emory Vaccine Center CRS, Decatur, Georgia, United States